GMP IPO Watch
ABH Healthcare IPO 2026 – Healthcare SME Issue in Focus
ABH Healthcare Limited's IPO is currently open for subscription after bidding began on August 24, 2026.
The company is looking to raise approximately ₹34.98 crore through a completely fresh issue of equity shares. There is no Offer for Sale, meaning the IPO is primarily a capital-raising exercise for the business rather than an exit for existing shareholders.
ABH Healthcare operates in the hospital and healthcare-services segment, with its core operations based in Ferozepur, Punjab.
ABH Healthcare IPO Details
| Particular | Details |
|---|---|
| Company | ABH Healthcare Limited |
| IPO Type | SME IPO |
| Issue Type | Book Built Issue |
| Issue Size | ₹34.98 Crore |
| Fresh Issue | ₹34.98 Crore |
| Offer for Sale | Nil |
| Shares Offered | 34,29,600 Shares |
| Price Band | ₹96 – ₹102 |
| Face Value | ₹10 |
| Lot Size | 1,200 Shares |
| Retail Minimum | 2 Lots / 2,400 Shares |
| Minimum Retail Investment | ₹2,44,800 |
| IPO Open Date | August 24, 2026 |
| Listing Platform | NSE SME |
The issue comprises up to 34,29,600 equity shares, valued at ₹34.98 crore at the upper price band of ₹102.
What Does ABH Healthcare Do?
ABH Healthcare was incorporated in 2021 and operates in the healthcare-services industry.
Its principal business is centred around hospital operations and providing medical services to patients. The company's operating model includes multiple clinical specialties supported by doctors, healthcare professionals, medical equipment and hospital infrastructure.
Unlike a pharmaceutical manufacturer that earns by selling medicines, ABH's economics are mainly linked to:
patient volumes → medical procedures → hospital occupancy → healthcare services → revenue.
This makes utilisation of its healthcare infrastructure an important factor in future growth.
Financial Performance Shows Strong Profit Improvement
ABH Healthcare has reported a noticeable improvement in profitability over the last three financial years.
| Particular | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Total Income | ₹41.39 Cr | ₹49.32 Cr | ₹52.59 Cr |
| EBITDA | ₹6.89 Cr | ₹13.20 Cr | ₹14.72 Cr |
| PAT | ₹1.66 Cr | ₹5.35 Cr | ₹5.64 Cr |
| Total Assets | ₹51.35 Cr | ₹63.90 Cr | ₹85.27 Cr |
| Net Worth | ₹6.30 Cr | ₹11.60 Cr | ₹17.27 Cr |
| Borrowings | ₹30.59 Cr | ₹33.78 Cr | ₹45.75 Cr |
Revenue increased from ₹41.39 crore in FY2024 to ₹52.59 crore in FY2026, representing growth of roughly 27% over the two-year period.
The improvement in PAT has been much stronger. Profit increased from only ₹1.66 crore in FY2024 to ₹5.64 crore in FY2026.
Margins Have Improved Considerably
ABH Healthcare's profitability improvement becomes clearer when looking at margins.
Current IPO financial data indicates an EBITDA margin of approximately 28.03% and PAT margin of around 10.74% for FY2026.
| KPI | FY2026 |
|---|---|
| EBITDA Margin | 28.03% |
| PAT Margin | 10.74% |
| ROE | 39.07% |
| ROCE | 19.09% |
| RoNW | 39.07% |
| Debt / Equity | 3.20 |
| EPS | ₹7.05 |
| NAV | ₹21.58 |
The relatively strong ROE and improving margins are positive indicators, but the debt-to-equity ratio of 3.20 also highlights the company's leverage.
Debt Is the Main Financial Metric to Watch
ABH Healthcare's borrowings have increased as the business has expanded.
Borrowings moved from ₹30.59 crore in FY2024 to ₹33.78 crore in FY2025 and ₹45.75 crore in FY2026.
| Financial Year | Borrowings |
|---|---|
| FY2024 | ₹30.59 Cr |
| FY2025 | ₹33.78 Cr |
| FY2026 | ₹45.75 Cr |
This increase explains why debt repayment is the biggest clearly identified use of the IPO proceeds.
₹17 Crore Planned for Debt Repayment
ABH Healthcare proposes to use ₹17 crore for repayment or prepayment of certain borrowings.
Another ₹5 crore is planned for working-capital requirements, while the remaining proceeds are intended for inorganic growth through unidentified acquisitions and general corporate purposes.
Use of IPO Proceeds
| Purpose | Amount |
|---|---|
| Repayment / Prepayment of Borrowings | ₹17.00 Cr |
| Working Capital Requirements | ₹5.00 Cr |
| Inorganic Growth & General Corporate Purposes | Balance |
| Total Issue Size | ₹34.98 Cr |
Debt repayment could be particularly meaningful considering FY2026 borrowings of ₹45.75 crore.
The potential financial impact is straightforward:
lower debt → lower interest costs → better cash flow → stronger balance sheet.
100% Fresh Issue Is an Important Feature
There is no OFS in the ABH Healthcare IPO.
| IPO Component | Amount |
|---|---|
| Fresh Issue | ₹34.98 Cr |
| Offer for Sale | Nil |
| Total Issue | ₹34.98 Cr |
This means the IPO proceeds are being raised for the company's requirements rather than existing shareholders selling their stake through the public offer.
For investors evaluating the IPO, the important question is how efficiently ABH deploys this fresh capital.
Hospital Utilisation Will Drive Future Growth
Healthcare businesses require substantial infrastructure.
Hospitals need:
doctors + nurses + diagnostic equipment + operating theatres + beds + pharmacy + emergency services + technology infrastructure.
Many of these expenses are fixed or semi-fixed.
This means higher patient volumes and better utilisation can potentially improve operating leverage.
For ABH, increasing utilisation of its existing infrastructure could therefore help revenue grow faster than certain operating costs.
Working Capital Is Important in Healthcare
Hospital operators can face delays between providing treatment and receiving payment.
This is particularly relevant where revenue comes through:
insurance companies + government schemes + institutional arrangements + corporate healthcare programmes.
The company has allocated ₹5 crore of IPO proceeds toward working capital.
Stronger working capital can provide additional flexibility as patient volumes and operations grow.
Future Acquisitions Could Become Another Growth Route
One interesting part of ABH Healthcare's IPO strategy is its intention to use a portion of proceeds for inorganic growth through unidentified acquisitions.
In healthcare, acquisitions can potentially help a hospital operator add:
new locations + hospital beds + doctors + specialties + patients + geographic reach.
However, acquisition-led growth also brings execution risk.
The company needs to ensure that any future acquisition produces adequate returns rather than simply increasing the size of the business.
Revenue Concentration Is a Key Risk
One of the more important risks disclosed around ABH Healthcare is its dependence on a single hospital located in Ferozepur, Punjab.
This creates geographic and operational concentration.
If the hospital experiences disruption, lower patient volumes, regulatory issues or increased local competition, the impact could be significant because the company currently lacks a large geographically diversified hospital network.
Future expansion could gradually reduce this concentration.
Hospital Premises Are Leasehold
Another factor worth noting is that the company does not own the premises from which its hospital operates; the facility is on a leasehold basis.
Lease-based operations can reduce the amount of capital required to purchase real estate.
However, they also create dependence on lease agreements and renewal terms.
For a hospital, relocation is considerably more complicated than moving a normal office because of medical infrastructure, equipment and patient accessibility.
Healthcare Professionals Are Critical to the Business
Hospital businesses depend heavily on doctors and specialised healthcare professionals.
Infrastructure alone cannot attract patients.
The actual value proposition comes from:
experienced doctors + clinical outcomes + specialised treatments + patient experience + hospital reputation.
ABH therefore needs to retain experienced clinicians while attracting additional specialists as it expands.
Competition for skilled healthcare professionals remains an important operating risk.
Technology Can Improve Hospital Efficiency
ABH's growth plans also include a more technology-oriented operating approach, including digital consultations and hospital-management systems.
Digital processes can potentially improve:
patient registration → consultation → medical records → billing → follow-up → revenue collection.
For a smaller hospital operator, better technology can help increase efficiency without proportionately increasing administrative costs.
ABH Healthcare IPO GMP
Current grey-market information remains limited.
One tracker reports no meaningful GMP, with the latest indication at ₹0 against the upper issue price of ₹102.
| GMP Particular | Latest Position |
|---|---|
| Upper Price Band | ₹102 |
| Latest Reported GMP | ₹0 |
| Indicative Price | ₹102 |
| Indicative Premium | 0% |
| GMP Sentiment | Neutral / No Active Premium |
GMP is an unofficial market indicator and can change quickly. It should not be treated as a guaranteed listing-price forecast.
Subscription Shows a Mixed Early Response
Current Day 2 tracking shows the issue still in the early stages of subscription, with QIB demand stronger than retail and NII participation.
One live tracker reported approximately 0.36× overall subscription, including QIB demand of 3.45×, retail at 0.33× and NII at 0.27× at the time of its latest update.
| Category | Latest Reported Subscription* |
|---|---|
| QIB | 3.45× |
| NII / HNI | 0.27× |
| Retail | 0.33× |
| Overall | ~0.36× |
*Live subscription figures can change throughout the bidding session.
Valuation at the Upper Price Band
At ₹102 per share, the IPO's current valuation indicators include:
| Valuation Metric | Value |
|---|---|
| Pre-Issue EPS | ₹7.05 |
| Post-Issue EPS | ₹4.93 |
| Pre-Issue P/E | 14.47× |
| Post-Issue P/E | 20.69× |
| Price / Book Value | 4.73× |
| NAV | ₹21.58 |
| RoNW | 39.07% |
| ROCE | 19.09% |
The post-issue earnings multiple is naturally higher because the fresh issue increases the number of outstanding shares.
Investors should therefore evaluate the valuation against future earnings potential rather than relying only on historical EPS.
Key Strengths of ABH Healthcare
ABH Healthcare enters the IPO with a profitable operating hospital business and a strong improvement in earnings over the last three financial years.
PAT increased from ₹1.66 crore in FY2024 to ₹5.64 crore in FY2026, while EBITDA increased from ₹6.89 crore to ₹14.72 crore.
The company also has a 100% fresh issue, with a significant ₹17 crore allocation toward debt repayment.
Its other strengths include a doctor-led management structure, diversified clinical specialties and established healthcare infrastructure.
Major Risks
The most important risks are the company's relatively high borrowings and concentration around a single hospital.
Other factors include dependence on doctors and healthcare professionals, regulatory requirements, medical litigation risk, technology and equipment investment needs, working-capital requirements and leasehold hospital premises.
The absence of a meaningful GMP also means there is currently limited indication of strong unofficial listing sentiment.
What Investors Should Track After Listing
| Metric | Why It Matters |
|---|---|
| Patient Volumes | Hospital demand |
| Bed Occupancy | Capacity utilisation |
| Revenue Growth | Business expansion |
| EBITDA Margin | Hospital efficiency |
| PAT Margin | Profit sustainability |
| Borrowings | IPO deleveraging |
| Finance Cost | Benefit from debt repayment |
| Working Capital | Cash efficiency |
| Operating Cash Flow | Earnings quality |
| New Specialties | Revenue diversification |
| New Hospitals / Acquisitions | Geographic expansion |
| ROCE | Capital efficiency |
For ABH Healthcare, debt reduction and diversification beyond its existing hospital could become two of the most important post-IPO developments.
Final View on ABH Healthcare IPO
ABH Healthcare's ₹34.98 crore NSE SME IPO is a 100% fresh issue priced at ₹96–₹102 per share. The company reported FY2026 total income of ₹52.59 crore, EBITDA of ₹14.72 crore and PAT of ₹5.64 crore.
The financial growth is encouraging, particularly compared with FY2024 PAT of only ₹1.66 crore. However, borrowings have also increased substantially and reached ₹45.75 crore in FY2026.
That makes the ₹17 crore planned debt repayment one of the most important aspects of the IPO. Another ₹5 crore is earmarked for working capital, while the company also intends to pursue inorganic growth opportunities.
